Breaking barriers for key populations in the lenacapavir era

Despite advances in human immunodeficiency virus (HIV) prevention, key populations including men who have sex with men (MSM), sex workers, transgender individuals, people who inject drugs, and adolescent girls and young women (AGYW) continue to experience disproportionately high rates of HIV infection and limited access to prevention services. The recent approval of lenacapavir, a twice-yearly long-acting injectable pre-exposure prophylaxis (PrEP), offers a promising opportunity to overcome adherence challenges associated with daily oral PrEP. However, its successful implementation hinges on addressing the structural and social barriers that have historically excluded these populations from benefiting fully from HIV innovations. While lenacapavir's discreet, long-acting profile holds great promise, its rollout may be undermined by persistent issues such as stigma, criminalisation, lack of youth-friendly services, and health system mistrust. Many individuals from key populations still face legal and social conditions that deter them from accessing clinics, even for biannual injections. Without intentional equity-focused strategies, including peer-led service delivery, policy reform, and community-based outreach, these same barriers could restrict uptake and impact. Innovative solutions such as integrating lenacapavir into trusted drop-in centres, mobile clinics, or combined reproductive health services can enhance accessibility and privacy. Ensuring equitable rollout also demands investment in key population-led organisations, disaggregated data monitoring, and rights-based policy frameworks that affirm agency and safety. Lenacapavir could be a game-changer for HIV prevention, but only if systems evolve to meet the needs of those most affected. Equity must be a deliberate foundation, not a secondary consideration. If we prioritise dignity, inclusivity, and structural reform alongside scientific innovation, lenacapavir can do more than prevent infections; it can help transform global HIV prevention into a tool for justice. The era of long-acting PrEP must not replicate old exclusions but rather break new ground in empowering key populations worldwide.

Authors

Institutions

Publication Details

Journal
Decoding Infection and Transmission
Published
2026-01-01
DOI
https://doi.org/10.1016/j.dcit.2026.100075
Citations
1
Primary Topic
HIV/AIDS Research and Interventions
Type
article
Field-Weighted Citation Impact
32.78
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Breaking barriers for key populations in the lenacapavir era

Abdulrahim Abdulrakib, Jamil Safayet, Victor Abiola Adepoju
1 citations
Decoding Infection and Transmission
HIV/AIDS Research and Interventions
32.78
article

Breaking barriers for key populations in the lenacapavir era

Abdulrahim Abdulrakib, Jamil Safayet, Victor Abiola Adepoju
article en
1 citations

Abstract

Despite advances in human immunodeficiency virus (HIV) prevention, key populations including men who have sex with men (MSM), sex workers, transgender individuals, people who inject drugs, and adolescent girls and young women (AGYW) continue to experience disproportionately high rates of HIV infection and limited access to prevention services. The recent approval of lenacapavir, a twice-yearly long-acting injectable pre-exposure prophylaxis (PrEP), offers a promising opportunity to overcome adherence challenges associated with daily oral PrEP. However, its successful implementation hinges on addressing the structural and social barriers that have historically excluded these populations from benefiting fully from HIV innovations. While lenacapavir's discreet, long-acting profile holds great promise, its rollout may be undermined by persistent issues such as stigma, criminalisation, lack of youth-friendly services, and health system mistrust. Many individuals from key populations still face legal and social conditions that deter them from accessing clinics, even for biannual injections. Without intentional equity-focused strategies, including peer-led service delivery, policy reform, and community-based outreach, these same barriers could restrict uptake and impact. Innovative solutions such as integrating lenacapavir into trusted drop-in centres, mobile clinics, or combined reproductive health services can enhance accessibility and privacy. Ensuring equitable rollout also demands investment in key population-led organisations, disaggregated data monitoring, and rights-based policy frameworks that affirm agency and safety. Lenacapavir could be a game-changer for HIV prevention, but only if systems evolve to meet the needs of those most affected. Equity must be a deliberate foundation, not a secondary consideration. If we prioritise dignity, inclusivity, and structural reform alongside scientific innovation, lenacapavir can do more than prevent infections; it can help transform global HIV prevention into a tool for justice. The era of long-acting PrEP must not replicate old exclusions but rather break new ground in empowering key populations worldwide.

Decoding Infection and TransmissionVol. 4
Universiti Putra Malaysia (MY), Johns Hopkins University (US), Daffodil International University (BD), Puntland State University (SO)
Reduced inequalities
Openalex Percentile: Top 2%
HIV/AIDS Research and Interventions
32.78
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.